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Background: Potential peripheral sources of deep pain can require invasive evocative tests for their assessment. Here
we perform research whose ultimate goal is development of a non-invasive evocative test for deep painful tissue.
Methods: We used a rat model of inflammation to show that intense focused ultrasound (iFU) differentially stimulates
inflamed versus control tissue and can identify allodynia. To do so we applied iFU to inflamed and normal tissue below
the skin of rats’ hind paws and measured the amount of ultrasound necessary to induce paw withdrawal.
Results: iFU of sufficient strength (spatial and temporal average intensities ranged from 100–350 W/cm2) caused the
rat to withdraw its inflamed paw, while the same iFU applied to the contralateral paw failed to induce withdrawal, with
sensitivity and specificity generally greater than 90%. iFU stimulation of normal tissue required twice the amount of
ultrasound to generate a withdrawal than did inflamed tissue, thereby assessing allodynia. Finally, we verified in a
preliminary way the safety of iFU stimulation with acute histological studies coupled with mathematical simulations.
Conclusions: Given that there exist systems to guide iFU deep to the skin, image-guided iFU may one day allow
assessment of patient’s deep, peripheral pain generators.
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A non-invasive diagnostic test that could reliably assess
subcutaneous, peripheral contributors to a patient’s pain
would be extremely helpful for diagnosing and treating
patients with pain of unknown origin. Current diagnostic
tests have limited ability to locate and assess the contri-
bution of subcutaneous tissue to a patient’s experience
of pain. For example, in up to 85% of patients with back
pain, imaging studies and physical examination cannot
pinpoint anatomic structures responsible for generating
the pain because they appear normal or because multiple
anatomic changes appear in images [1], all complicated
by the likely presence of central sensitization [2]. Evoca-
tive tests such as discography address the non-specificity* Correspondence: pierre@apl.washington.edu
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reproduction in any medium, provided the orof imaging for locating pain by correlating the patient’s
report of pain with increased intradiscal pressure generated
by injection of fluid within the disc. Unfortunately, this
approach is invasive and uncomfortable for the patient.
Moreover it tests only a subset of candidate peripheral pain
generators, hence has relative low sensitivity and specificity.
As reviewed by Woolf [2], contributions to a patient’s
experience of pain caused by central sensitization include
pain from normally non-painful stimulation (allodynia),
increased pain response to normally painful stimulation
(hyperalgesia), enhanced temporal summation, (where a
patient’s experiences increased pain during the application
of a series identical but rapidly applied stimuli) and the
possibility that subclinical but irritating signals from deep
peripheral tissue chronically stimulate and thereby main-
tain central sensitization. With this insight, current clinical
practice for chronically painful diseases has begun to as-
sess these characteristics of pain in patients compared
to healthy controls. For example, clinicians use pulses ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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to the skin of potential fibromyalgia patients that gener-
ally produces more intense sensations or even pain, of
duration generally far beyond that of the stimulation
itself, when compared to its application to healthy test
subjects [3-6]. Though comparable results have been
produced by focal application of pressure to the skin in
a manner shown to activate subcutaneous sensory fibers
after application of a topical anesthetic [4], this method
of assessing the extent of pain cannot isolate potential
sources of subcutaneous peripheral irritation since its
stimulation involves all subcutaneous tissues.
We believe that the clinical management of pain as-
sociated with subcutaneous tissue could benefit from a
non-invasive, targeted and quantifiable evocative test
for deep-tissue pain. Intense focused ultrasound could
form the basis of this test. Specialized ultrasound devices
can focus quantifiable amounts of ultrasonic energy within
a roughly cylindrically shaped volume of tissue on the
order of tens of microliters that lies subcutaneous within
the body [7,8] sufficient to cause rapid, transient, and
localized increase in tissue temperature. Such devices
can also cause local tissue displacement, hence localized
shear forces within tissue [7,8]. In sufficient quantities
(generally greater than 1000 W/cm^2 with application
times greater than a second), the heat, shear, and/or
cavitation – the formation and activation of mechanically
active bubbles by ultrasound [8] – can destroy tissue
[9-11]. Such ultrasound, of high intensity and designed
to alter tissue properties generally for therapeutic purposes,
is generally known as high intensity focused ultrasound –
HIFU. Using the same HIFU technology but with shorter
durations and lower intensities, intense focused ultrasound
(iFU) can safely induce discernible sensations in human
subjects [12,13].
Given this insight, Gavrilov [12,14,15], Wright [16],
and their colleagues suggested that iFU applied to tissue
associated with a potential neuropathic injury would
elicit abnormal sensations discernibly different from
those elicited by iFU applied to normal tissue. We have
successfully tested their hypothesis directly [17,18]. We
have also observed that diurnally inflamed tissue varies in
its response to individual and short pulses of iFU [19]. In
addition we studied the effect of multiple and rapidly
delivered short pulses of iFU applied to inflamed tissue
compared to contralateral tissue [20].
Here we sought to test the hypothesis that iFU
can differentiate inflamed, diffusely painful subcuta-
neous tissue from contralateral subcutaneous tissue.
We also assessed whether or not iFU could diagnose
allodynia by using separate cohorts of animals to
compare iFU threshold values of inflamed tissue and
normal tissue. Finally we present histological results
consistent with the safety of this procedure and calculationsthat assess the likelihood of damage caused by our
iFU protocols.
Materials and methods
All animal procedures were approved by the Institutional
Animal Care and Use Committees of both the University
of Washington and the Veterans Administration of Puget
Sound.
Animal model of peripheral inflammatory pain
Adult male Fischer rats (approximately 180 g, Charles River)
were anesthetized with a 5% Isoflurane (Pitman-Moore,
Mundelein, IL) and oxygen mixture via nose cone for induc-
tion. The concentration was decreased to 2% Isoflurane for
maintenance of the anesthetic. Inflammation was induced
using methods adapted from Nagakura et al. [21]: 0.2 ml
of Complete Freund’s Adjuvant (CFA, Sigma Aldrich) was
injected subcutaneously over 45 seconds into the plantar
surface of the right hind paw at the base of the toes using
a 25 g 5/8” needle. This produced significant inflamma-
tion throughout the right hind paw — from skin to peri-
osteum — with maximum sensitivity observed 5–7 days
after injection [21]. A separate group of rats did not receive
the CFA injection, serving as normal controls to allow
assessment of allodynia by comparison of iFU stimulation
values for inflamed versus normal paws.
Ultrasound devices and acoustic protocols
For this study we used two ultrasound devices, which
we first summarize here. We used a device optimized
for subcutaneous stimulation for our behavioral studies,
which assessed allodynia. We used a laser-guided device for
the safety studies where we applied iFU to very specific,
subcutaneous tissue, facilitated by use of lasers to identify
the focus in tandem with a micropositioning device. This
allowed us to assay in a preliminary way the margin of
safety of subcutaneously delivered iFU for stimulation by
identifying sufficient iFU to cause acute, observable tissue
damage. The center of the focus (peak pressure value)
occurred within 4–7 mm beyond the tip of both devices.
The transducer used for our behavioral studies gener-
ated ultrasound using the inner element (22.6 mm inner
diameter, 48.5 mm outer diameter) of a two-element,
1.1 MHz transducer (H-105 S/N-01 Sonic Concepts,
Inc., Bothell, WA). Ultrasound was beamed to the tissue
of interest through a plastic removable cone mounted
on the transducer and filled with degassed water. The laser-
guided device for our safety study consisted of a 2 MHz
single-element (35 mm diameter) focused transducer
(SU-101 - http://www.sonicconcepts.com/images/pdf/
su-101_datasheet.pdf, Sonic Concepts, Inc., Bothell, WA)
on which a plastic removable cone was mounted on
the transducer and filled with degassed water facilitate
ultrasound propagation as above. Mounted permanently
McClintic et al. Journal of Therapeutic Ultrasound 2014, 2:8 Page 3 of 9
http://www.jtultrasound.com/content/2/1/8on the sides of this cone were 2 lasers (Digi-Key, Thief
River Falls, MN) pointed at the center of the ultrasound
focus, useful here for directing the focus of our device
to the appropriate exposed tissue for our safety study.
Acoustic field maps were generated for both transduc-
ers. The acoustic pressure was simulated using custom
MATLAB (The Mathworks, Inc., Natick, MA) software
written in-house for modeling arbitrary transducer geom-
etries assuming linear acoustics [22,23]. With those simula-
tions we calculated the full width half maximum (FWHM)
pressure, the intensity, and the fractional ultrasound power
within the FWHM as well as the area within the FWHM
for each transducer [23,24]. Table 1 provides the geometric
specifications of our transducers.
The transducers were driven by an amplifier (A150 RF
Power Amplifier, ENI, Chesnut Ridge, NY) controlled by
two function generators (33120A, Hewlett Packard/Agilent,
Palo Alto, CA). The first generator gated the pulse to a
specific duration. The second, in series with the first,
modified the acoustic output and ensured that the pulse
was emitted at a specific frequency. The amplifier increased
the signal from the function generators and sent it to the
device. An oscilloscope (Wave Runner LT 322, LeCroy,
Chesnut Ridge, NY) measured the duration of the pulse,
its carrier frequency and the voltage delivered to the iFU
device by the amplifier during each experiment.
The acoustic output of each transducer as a function of
input voltage was measured using a radiation force balance
[24]. Our intensity measures are reported in terms of spatial
average temporal average intensity, ISATA, which we define
as the total acoustic power of the transducer at a given in-
put voltage times the fractional power within the FWHM
divided by the area enclosed by the FWHM [23,24].
We also applied a pulse of 0.375 seconds using the be-
havioral device to the paws of both normal rats and those
with inflamed paws in order to demonstrate that iFU can
be used to assess allodynia in subcutaneous tissue.
Behavioral data collection - Hargreaves and iFU application
to rats
We performed our studies starting five days after CFA in-
jection. Groups of three rats underwent a set of Hargreaves
heat pain paw withdrawal tests [25], followed by application
of iFU and then another set of Hargreaves tests, all during
the daytime of a single day, with each test separated from
the next by an hour of waiting time. Rats were placed in
separate compartments in a Plexiglas cage with a glass floor,Table 1 Geometric parameters of our ultrasound devices




Behavioral 0.6 mm 7
Laser-guided 0.8 mm 8and an intense light was applied serially to each rear paw of
each rat through the floor via a focused lamp. When the rat
withdrew its paw the lamp was turned off and the time to
withdrawal was recorded. The lamp automatically turned
off if the rat did not withdraw its paw after 20 seconds. All
data was recorded in seconds. We repeated this test five
times for each rat.
After heat lamp testing, we habituated sets of three rats
to their free-ranging presence within individual cages con-
taining three separate enclosures, each with a mesh bottom
(rather than plexiglass bottom) whose individual holes were
large enough to allow the researcher to pass through the
distal tip of the ultrasound device to the bottom of the rat’s
feet (Figure 1). Within this experimental setup we habitu-
ated the rats to a light touch of the iFU transducer and
acoustic gel (Aquasonic 100 Ultrasound Transmission gel,
Parker Laboratories Inc.) to the plantar aspect of their paws
such that the rat would not move its paw despite the touch.
This light touch plus use of a small volume of ultra-
sound gel placed between the transducer and the rat’s
paw ensured adequate acoustic coupling between the
two. Habituating the rats to the device took approxi-
mately 5 minutes per set of three rats, as indicated by
an absence of reaction to the touch of the transducer
and a lessening of exploratory movements.
After habituation we again placed the proximal surface
of the device up through the holes within the bottom of the
mesh cage until that proximal surface touched the bottom
of one of the rat’s hind paws, again using ultrasound gel to
ensure adequate coupling. (Note that if during the iFU test
procedure a rat began to withdraw its paw in response to
contact with the device plus gel but without iFU applica-
tion, it was re-habituated to the touch of the device plus
gel before re-starting iFU threshold testing). This time we
applied a single pulse to the plantar surface of the paw,
seeking to observe an immediate and rapid withdrawal of
the stimulated hind paw. We then applied iFU to the
other hind paw in each of the three rats after a minimum
of 30 seconds. The order of paw testing was randomized
based on the rat’s position in the cage. In the absence of a
hind paw withdrawal response the intensity of ultrasound
was increased in increments beginning at 30% and taper-
ing to 10% increase as intensity increased, starting with an
initial acoustic intensity of approximately 50 W/cm2. Rats
showing only one out of two withdrawal responses to a
given level of iFU stimulation at a given power on a given
paw were considered negative tests and the intensity wasxial length at half
aximum pressure
% of energy within length of
beam at half maximum pressure
.5 mm 44.7%
.45 mm 70%
Figure 1 Diagram of our experimental setup for determination
of iFU withdrawal threshold. A rat is placed on top of a mesh
grid, allowing us to deliver iFU through the floor to the plantar
aspect of the rat’s paws. Ultrasound gel is used to ensure adequate
coupling of the device.
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threshold intensity at a given duration that induced two
consecutive withdrawal responses from a given paw. If
rats withdrew both hind paws to a given iFU intensity
the acoustic intensity was decreased and iFU was re-applied
until only one paw withdrawal response was observed twice
after each of two consecutive applications of iFU to that
paw or we determined that we could not identify a single
sensitive paw (see flowchart in Figure 2). In our experience
this entire experimental procedure required one to two
hours of effort for a set of three rats.
The intensity and dose of iFU that caused two con-
secutive withdrawals on the same paw for a given rat
was defined as the iFU threshold value for that rat on
that day. iFU was then applied six more times at that
same value to facilitate calculations of sensitivity and
specificity. We applied iFU to each rat on separate test-
ing days. No rat received an entire iFU test more thanFigure 2 Flowchart of the iFU threshold determination process.once per day, with at least 1 day between each test. After
testing, rats were returned to their cages and then returned
to the animal housing facility.
Data analysis
Data was entered into an Excel (Microsoft, Redmond, WA)
spreadsheet where the intensity and dose of each acoustic
protocol, latency times measured from the Hargreaves test,
etc., were calculated and reported as aggregates in terms of
an average +/− standard deviation. Differences in acoustic
intensity or Hargreaves latency times between groups were
evaluated by analyses of variance with Tukey’s tests for
appropriate post-hoc comparisons (GB Stat; Dynamic
Microsystems; Silver Springs, Maryland). Differences
between two groups of data are reported as statistically
significant if the p-value < 0.05.
We calculated the sensitivity and specificity of iFU appli-
cation to the paws using data from both the iFU threshold
value determination plus the six additional iFU applications
of that same iFU threshold value to each of the rat’s rear
paws. We define sensitivity as the number of withdrawal
responses on the injured paw to the threshold intensity
divided by the total applications to that paw at that in-
tensity. Similarly, we defined the specificity as the num-
ber of applications of iFU at the threshold intensity to
the uninjured paw that elicited no response divided by
the total number of applications to that paw.
We used box plots to represent our results, where the
line in the box gives the median value, the box encom-
passes the position of 75% of the values, the whiskers
bound 95% of values and individual points represent in-
dividual values that extend beyond the 95% boundary.
Safety data collection and calculations
iFU application to exposed thigh muscle
In parallel to behavioral studies that anticipate application
of this methodology to subcutaneous muscle, we collected
acute safety data to demonstrate the margin of safety
of stimulating skeletal muscle via iFU application. We
elected to study muscle instead of the paw because
histology experts suggested to us that the heteroge-
neous damage caused by the inflammation would likely
obscure any damage caused by iFU. Therefore, we applied
iFU directly to skeletal muscle at an intensity comparable
to the threshold established in the behavioral studies, and
systematically increased this value until we observed acute
tissue damage deep to the surface of the exposed muscle
using histological analysis. In our pilot studies we found
that ultrasound comparable in intensity and dose to those
used in our behavioral tests did not cause any acute
damage (data not shown). We therefore selected for
reporting here the histological effects of iFU at signifi-
cantly larger intensity and acoustic dose values substan-
tially greater than anything used in behavioral tests. In
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stimulation.
Seven adult Sprague Dawley rats (approximately 200 g,
Charles River) were deeply anesthetized with a 5% Isoflurane
(Pitman-Moore, Mundelein, IL) and oxygen mixture via
nose cone for induction and 2% Isoflurane for mainten-
ance of the anesthesia. 0.1 mL of lidocaine was injected
subcutaneously in the hind limb and a 2-cm long incision
was subsequently made to expose the muscle at the mid-
thigh level. The skin was retracted to the medial side and
the biceps femoris muscle was exposed and dissected from
surrounding fascia. Using 3–0 silk sutures to indicate the
area of intended iFU application, calibrated lasers attached
to the iFU device were used to place iFU application
within the bounds of the suture markers. One iFU dose
was applied per thigh.
Within an hour of iFU application, the animals were
sacrificed with Beuthanasia (phenytoin, 390 mg/mL
pentobarbital) and perfused via transcardiac injection
with 4% paraformaldehyde in phosphate buffer. Then
we dissected out a 1 cm3 tissue sample, taken from at and
below the surface of the muscle at mid-thigh level from the
ipsilateral side, as indicated by the sutures applied
prior to application, along with comparable tissue from
the contralateral hind limb. Tissue specimens were
post-fixed in 4% paraformaldehyde in phosphate buffer,
immersed in sucrose for cryoprotection, and embedded
in diethylene glycol (OCT) for frozen sectioning. Serial
sections (10 μm) were obtained using a cryostat at −20°C.
These sections were stored in a freezer at −80°C and later
stained using Hematoxylin & Eosin.
Theoretical estimation of the chance for damage due to
iFU stimulation
We wished to further assess the possibility that our iFU
stimulation protocols could cause damage via tissue heating
to the rats’ paws. To do this, we estimated the minimum
intensity of iFU necessary to cause tissue damage based on
theoretical concerns, given the parameters of our device
and pulse duration. We then compared the estimated
threshold for damage with the results of our behavioral
studies. To calculate the estimated iFU damage thresh-
old, we utilized the quantity ‘time for equivalent thermal
dose’ (t43) as an intermediate variable.
The calculation to estimate the iFU damage threshold
is described in the following steps:
(1) In MATLAB, we calculated the heat generated by
our iFU device throughout a uniformly space grid in
a 1 cm × 1 cm plane, normal to the axis of
ultrasound propagation at the focus. We used a
temporal step-size of 1 ms and total duration of 10s.
The spatial structure of the intensity field for the
transducer was scaled according to the spatialaverage temporal average (SATA) intensity under
simulation. Tissue within the plane was assumed to
be striated muscle. The tissue parameters used in
the simulation are shown in Table 2 [26]. We used
the attenuation coefficient in our calculations, which
includes losses due to absorption and scattering but
is dominated by absorption [22].
(2) We used the Bioheat equation [27] to estimate the
time variation in temperature generated by the heat
generated by our device. We included thermal
conduction, but not perfusion, for this calculation.
(3) We calculated the equivalent thermal dose (t43)
using the time-varying temperature generated in
step 2 in the equation below, where T is the
temperature in °C and R is 0.5 for temperatures
greater than 43°C and 0.25 for temperatures below
43°C [28]. The rat baseline body temperature is
assumed to be 38°C [29]. Thermal damage is estimated
to occur at a t43 of 240 minutes, or the equivalent of




tR 43−T tð Þð Þdt
(4) We followed steps 1–3 across a range of intensities,
in order to determine at what intensity the t43 would
reach the 240-minute damage threshold. This intensity
was recorded as the minimum intensity at which
thermal damage might occur.
Results
Hargreaves results
Hargreaves testing on the rats did not alter the iFU thresh-
old values. iFU did not alter the Hargreaves threshold values,
whose average value equaled 4.1 seconds +/− 1.2 on the in-
flamed paw and 8.2 seconds +/− 1.7 on the normal paw.
Assessment of allodynia for subcutaneous delivery of iFU
We performed twelve tests on nine rats with inflamed paws
and nine tests on six rats with normal paws using a single
acoustic pulse of 0.375 seconds in duration. We were able
to identify iFU threshold values for all tests on rats with in-
flamed paws: the inflamed paw withdrew first 100% of the
time. Also, we were able to identify iFU threshold values
for all tests on rats with normal paws, with no difference in
the number of right versus left paws responding first. The
threshold intensity and dose values were significantly higher
(p < 0.0001) for the control rats with normal paws versus
Figure 4 Histology. A. Sectioned muscle after 20 applications of
0.1 s iFU pulses at an intensity of 1000 W/cm2 and dose of 2000
(W*s)/cm2) per pulse. The tissue was undamaged after this application.
Large image is 4X magnification, inset is 10X. B. Sectioned muscle after
30 applications of 0.1 s iFU pulses at an intensity of 2000 W/cm2 and
net dose of 6000 (W*s)/cm2). This tissue sample shows damage. Large
image is 4X magnification, inset is 10X.
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factor of two (Figure 3).
Sensitivity and specificity of iFU stimulation
As discussed in the methods section we used the initial
two applications of iFU to determine the threshold iFU
value. We combined those data points with the six add-
itional applications of iFU at the iFU threshold value to
calculate values of sensitivity and specificity. The sensi-
tivity for the inflamed paws was 89.6% +/− 10.4% and
the specificity was 88.5% +/− 12.5%. The sensitivity for
the control rats with normal paws was 82.6% +/− 14.9%
and we did not assess specificity of the normal paws.
Safety studies based on histology
Twenty separate 0.1 s applications of iFU spaced ten sec-
onds apart at an intensity of 1000 W/cm2 produced no
observable cellular damage in tissue taken from seven
animals (Figure 4A). In contrast, 30 separate applications
of iFU spaced ten seconds apart, each with a duration
0.1 s at an intensity of 2000 W/cm2 did produce observable
damage acutely in 4 animals (Figure 4B), observed at the
focus: 4 mm below the surface of the tissue encompassing
an area of tissue measuring 1–2 mm in diameter.
Safety studies based on theoretical concerns
We calculated the threshold for potential thermal damage
in order to add another measure for the safety of our proto-
col. We used muscle as the model tissue, as this is most
representative of the tissue that we believe the device
stimulated. We found that over 40% of our tests yielded
threshold results above the dose estimated to cause thermal
damage. Table 3 summarizes these results. We have also
marked the intensity value associated with the theoreticalFigure 3 Assessing allodynia with the deep focus iFU device.
Intensity (left axis) and dose (right axis) of iFU necessary to produce
a reliable withdrawal from each of inflamed and normal paws, for
the deep focus device. ‘CFA’ refers to rats whose rear paws were
inflamed with Complete Freunds Adjuvant while ‘normal’ refers to
rats with uninjured paws. The dashed line represents the value at
which (or above) thermal damage may occur.possibility of damage on Figure 3 to give the reader a visual
representation of the data.
Discussion
We tested the hypothesis that iFU stimulation could as-
sess allodynia associated with subcutaneous painful in-
flamed tissue. We performed this test by applying iFU to
the inflamed, contralateral and normal hind paws of rats,
and observed the iFU intensity and dose at which they
withdrew their paws from the device in a consistent
fashion. We also tested the safety of this procedure by
determining the amount of iFU necessary to cause acute
damage in muscle relative to our observations of with-
drawal behavior by iFU application – a measure of the
margin of safety of iFU stimulation. We also calculated
estimates of the threshold intensity and dose of iFU neces-
sary to cause damage and compared those to our observa-
tion of the amount of iFU necessary to cause a withdrawal
from iFU application.
Table 3 Potential damage threshold values by acoustic
protocol and device
Tissue type Muscle
Acoustic protocol 0.375 s
Potential damage threshold (W/cm2) 286.0
% of data above t43 CFA Normal*
41.7% 100%
*note that we tested both CFA-injected animals and normal animals for this
duration with the deep device.
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rats’ paws had significantly different iFU withdrawal
thresholds, and those differences correlated well to the
standard Hargreaves’ heat lamp test. The correlation of
significance between the standard test and the iFU test
indicates that iFU threshold for pain or sensation is a
reasonable metric for assessing allodynia, important for
diagnosing, hence treating chronic pain or other central
and/or peripheral nervous system disorders.
We showed functional and histological data consistent
with the hypothesis that these iFU protocols do not cause
tissue damage. Specifically, the Hargreaves heat withdrawal
latencies did not change after iFU application, offering evi-
dence that the rat’s ability to sense thermal stimulation did
not change due to iFU stimulation. In addition, we note
that Gavrilov, Wright, Dalecki, Dickey, and colleagues ap-
plied comparable amounts of ultrasound to themselves and
to test subjects without incident [13-16,30]. Moreover, the
dose of ultrasound necessary to produce damage to muscle
tissue acutely (measured here with histological analysis)
was more than 100 times that necessary to cause the ob-
served withdrawal. This preliminary measure of the margin
of safety of iFU stimulation is also consistent with published
studies of the amount of ultrasound necessary to cause
damage in peripheral nerve, a candidate target tissue for
the present technology. Specifically, Foley et al. [31] found
that an intensity of 7,890 W/cm2 and duration 5 seconds
[hence a dose of almost 40,000 (W*s)/(cm2)] was required
to cause acute damage of peripheral nerves. However, we
note that all t43 calculations (a very conservative means of
estimating the potential of thermal damage), when applied
to deep-tissue data, suggested that we might have damaged
tissue a meaningful percentage of the time, though, again,
our direct histological analysis suggests otherwise. We
discuss this possibility below.
Limitations
There are several limitations of our research that motivate
future work on this subject: our choice of tissue for the
safety studies, our estimates of the temperature induced
by iFU during our studies, and the means by which iFU
may have stimulated the paws of our rats.
With regard to our safety study, we chose to assess
potential acute damage induced by iFU using exposedmuscle of Sprague Dawley rats as target tissue, while for
the behavioral studies we used the inflamed, contralateral,
and normal paws of Fisher rats as target tissue. We chose
relatively homogenous muscle tissue as our target for the
safety study rather than tissue from the paws of our rats,
following the advice of our local histopathologist. Based
upon her experience with this kind of tissue she strongly
suggested we would find it difficult to identify iFU-induced
damage relative to the extensive damage created by the in-
flammation. In addition, we chose tissue from a different
strain of rat in order to conserve the number of rats used
for our study. Specifically, the Sprague Dawley rats were
from a parallel study and used here for the acute safety
study after they had served their purpose in that parallel
study. Future work will consider the long-term effects of
varying amounts of repeated stimulation by iFU of tissues
directly relevant to a given clinical target. Of particular
interest may be study of the structure and function of the
peripheral nerves in tissue subjected to iFU stimulation.
Here, electron microscopy of the peripheral nerve terminals
may show subtle alteration of their structure that histopath-
ology would miss.
In addition, we estimated temperature changes induced
by iFU during our study through use of the bioheat
equation applied to a homogeneous and infinite expanse
of tissue. We did so in order to calculate the minimum
intensity and dose of iFU that may produce thermal
damage. For those calculations we included diffusion
but not perfusion, thereby reducing the mathematical
complexity, and used reported values of attenuation, a
function of absorption plus scattering, more typically
measured than absorption alone. These assumptions make
our calculations conservative, where they would otherwise
reach a higher value were we able to perform simulations
that are more realistic. This is of interest because we pre-
dicted the possibility of iFU induction of thermal damage
to deep, normal tissue for 40% of the time through our
use of iFU during some of our experiments, which does
not match our histological assay of potential damage, de-
scribed above. Perhaps one reason for this difference is
that we did not constrain the animals to experience the
entire iFU application. Indeed, we identified a successful
stimulation by iFU by its ability to induce the rat to with-
draw its paw. Therefore, they might have withdrawn their
paw after successful iFU stimulation before we delivered
the entire dose of iFU. Nonetheless, we recognize that the
paws of rats as well as clinically relevant tissue in humans
are structurally and functionally much more complex than
what we have assumed in our metric for thermal damage.
Therefore, careful quantification of the actual iFU applica-
tion time, along with more representative simulations –
necessarily much more complex than those considered
here – might become warranted as we move closer to
human applications of this technology.
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paws is worth detailed discussion here. Ultrasound can
indeed cavitate tissue. An argument against that occurring
here lies in the fact that the dose values we observed to be
necessary to cause a paw withdrawal by the rats were
mostly under 200 (W*s)/(cm2) in uninjured paws. These
are substantially smaller than those demonstrated as
necessary to create cavitation in vivo – approximately 800
(W*s)/(cm2), as measured by Hynynen and colleagues
[32], albeit at a different frequency. (Of course, the ob-
served threshold for cavitation in vivo could only measure
cavitation amenable to detection with their device and
may therefore have missed cavitation events sufficient to
generate sensations.) Nonetheless, we recognize that we
inflamed the paws of the rats via injection of Complete
Freunds Adjuvant and thereby likely have introduced
cavitation nuclei into the tissue. These cavitation nuclei
may, in principle, have survived the five to seven days
that transpired before we performed our behavioral
studies. This possibility seems unlikely to us, however,
given the short life of even structured cavitation nuclei
(acoustic contrast agents) in blood [33]. Still, we recognize
that another explanation for the means by which iFU
caused sensations within the paws of our rats is that in-
flamed paws contain cavitation nuclei while normal paws
do not, and that mechanical stimulation by iFU-induced
cavitation may have stimulated the rat’s paws. The possi-
bility that cavitation played a role in our studies therefore
supports future behavioral studies that simultaneously as-
sess cavitation activity as well as use of degassed CFA.
Conclusion
There exist magnetic resonance imaging (MRI) guided
systems that facilitate the delivery of focused ultrasound
deep to the skin [7,9,11]. Given this, our work points
to the possibility that iFU – necessarily under image
guidance - could serve as a non-invasive method of
stimulating hence identifying injured subcutaneous tissue,
thereby locating a deep, peripheral anatomical correlate to
a patient’s pain. For example, iFU could stimulate individ-
ual nerves of amputee patients to create better surgical
outcomes, or for implementation of prosthetics. MRI-
guided iFU may also help to target tissue for optimal
ablation via high intensity focused ultrasound (HIFU)
by first locating painful tissue, and may serve as a useful
diagnostic technique to guide other treatment modalities.
This same method may one day offer a means of assessing
allodynia associated with that subcutaneous tissue. Such
an approach may also benefit from complementary
monitoring of EEG patterns, as has been done for cuta-
neous stimulation [4]. This idea is consistent with the
original work of Gavrilov and colleagues [12,14,15] and
suggested by Dalecki et al. [30], and Wright et al. [16],
along with our more recent work [17-19]. Given thisperspective, successful, definitive testing of image-guided
iFU as just described would herald the creation of a new
tool for assessing pain associated with subcutaneous ana-
tomical structures, providing useful diagnostic data to guide
its treatment, and tracking its treatment through time.
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